NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, announces a major milestone in its corporate growth strategy with the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms: JumpstartRx and NueVistraMed. Under the terms of the definitive agreements, NexTel will acquire both entities for a total consideration of $8 million, consisting of $2 million in cash and $6 million in preferred stock.
Read the full article: NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed //
Source: https://www.globenewswire.com/news-release/2026/06/02/3305430/0/en/nextel-medical-corp-executes-definitive-purchase-agreements-to-acquire-jumpstartrx-and-nuevistramed-expanding-telehealth-footprint-and-accelerating-maxasome-commercialization.html